Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 9 Nov 2026
Promising but preliminary

Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors (BTKi): A Retrospective Study From a Tertiary Healthcare Center in North India.

This retrospective, single-center study analyzed data from 41 patients with CLL treated with BTKi between January 2019 and November 2024. BTKi therapy is effective and well tolerated in Indian CLL patients, but early discontinuation highlights the need for improved adherence strategies.

This retrospective, single-center study analyzed data from 41 patients with CLL treated with BTKi between January 2019 and November 2024. BTKi therapy is effective and well tolerated in Indian CLL patients, but early discontinuation highlights the need for improved adherence strategies.

What the study was

Study design
Retrospective observational study
Population
n=41
Sample size
n=41
Category
Other
Maturity
Validated
Journal
Cureus

Why it surfaced

⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Hematologic malignancies; Design: Retrospective observational study; species: human

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.